Eisai (United States)

Recent papers from Eisai (United States)

1. Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden2026
2. A phase 2 trial evaluating polysomnography outcomes and safety of lemborexant in Korean adults with insomnia disorderScientific Reports · 2026
3. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyThe Lancet · 2025
4. Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer DiseaseJAMA Neurology · 2026
5. From Biomarker Anchors to Disease-State Transitions: A Biologically Anchored Probabilistic Principal Component Analysis Framework for Alzheimer’s Disease Progression ModelingNeurology and Therapy · 2026
6. Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding studyGynecologic Oncology · 2026
7. E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohortEClinicalMedicine · 2026
8. More efficient screening for preclinical Alzheimer's clinical trials using mixture of expertsAlzheimer s & Dementia · 2026
9. Evaluation of vancomycin bolus/standard and continuous infusion on nephrotoxicity in a rat modelInternational Journal of Antimicrobial Agents · 2026
10. Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping reviewAlzheimer s & Dementia · 2026
11. Alzheimer's disease heterogeneity and co‐pathologies: Defining novel targets, biomarkers, modalities, and research methodologiesAlzheimer s & Dementia Translational Research & Clinical Interventions · 2026
12. Emerging directions in tauopathy researchAlzheimer s & Dementia · 2026
13. Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progressionAlzheimer s & Dementia Translational Research & Clinical Interventions · 2026
14. Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide CohortJCO Precision Oncology · 2026
15. Leveraging E7386 phase 1 trials for cardiac safety: Gaining concentration-QTc insights to inform early-stage oncology development.Journal of Clinical Oncology · 2026
16. Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial.Journal of Clinical Oncology · 2026
17. First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and NeckCancer Science · 2026
18. First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF -mutated differentiated thyroid cancer (DTC): Insights from real-world data.Journal of Clinical Oncology · 2026
19. Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer DiseaseJAMA Neurology · 2026
20. Real‐world use of lecanemab: patient pathway findings from a US multicenter studyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026